Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

SAN DIEGO, March 19, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company’s President and Chief Executive Officer, Kristin Yarema, Ph.D., will participate in a virtual fireside chat at the H.C. Wainwright 2^nd Annual Cell Therapy Virtual Conference on Tuesday, March 26, 2024 at 1:00pm PT | 4:00pm ET.

A live webcast of the fireside chat will be available on the Investors & Media Section of Poseida’s website, www.poseida.com. A replay of the webcast will be available for approximately 90 days following the presentation.

About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company’s pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. The Company’s approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac^® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System, Booster Molecule, and nanoparticle and hybrid gene delivery technologies as well as in-house GMP cell therapy manufacturing. The Company has formed a global strategic collaboration with Roche to unlock the promise of cell therapies for patients with hematological malignancies. Learn more at www.poseida.com and connect with Poseida on X and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-hc-wainwright-2nd-annual-cell-therapy-virtual-conference-302092083.html

SOURCE Poseida Therapeutics, Inc.